Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$6.32
--
Market closed
$6.32
--
Day’s Range― - ―
52-Week Range$2.14 - $11.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.22K
Market Cap
$106.08M
Enterprise Value-$1.97M
Total Cash (Recent Filing)$117.98M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 20, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.21
Shares Outstanding22,928,303
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit197.04
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$10.50Price Target Upside66.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Addressable Market OpportunityAnalyst points to a large unmet need in VEGF-driven retinal diseases, where capturing even a modest market share with a longer-lasting treatment could translate into meaningful commercial results.
Early Efficacy And PharmacokineticsEarly clinical data indicated improvements in vision and retinal anatomy plus a pharmacokinetic profile consistent with prolonged intraocular residence, suggesting the therapy could deliver meaningful patient benefits.
Molecular Design And DurabilityAnalyst highlights TH103's engineered molecular design that increases binding to eye tissue and may extend time between injections, offering a potential clinical and commercial advantage over existing therapies.
Bears Say
Clinical Trial Interruption And Timeline RiskPause of the multiple-ascending-dose study to implement purification refinements requires re-enrollment of a cohort and delays completion of the dose-finding work and the top-line readout.
Development And Regulatory UncertaintyCompany remains a clinical-stage developer, so development and regulatory risk create significant uncertainty around whether TH103 will ultimately achieve approval and commercial success.
Manufacturing-related Safety ConcernsIntraocular inflammation events attributed to residual host cell proteins highlight a manufacturing quality issue that raises safety risks and must be resolved for further development.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $106.08M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 12 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Mar 17, 2026. The company reported -$0.535 earnings per share for the quarter, beating the consensus estimate of -$0.586 by $0.051.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 22,928,303 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.535 in its last earnings report, beating expectations of -$0.586. Following the earnings report the stock price went down -3.292%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (66.14% Upside)
$10.50 (66.14% Upside)
Hedge Fund Trend
Decreased
By 141.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
-73.11%
Trailing 12-Months
Asset Growth
2.69%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
KLRS Stock 12 Month Forecast
Average Price Target
$10.50
▲(66.14% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
56.49% Insiders
2.06% Mutual Funds
1.21% Other Institutional Investors
38.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---